Completion Thyroidectomy in a Patient with Differentiated Thyroid Cancer

  • Serdar Özbaş
  • Seyfettin Ilgan


A considerable number of patients, undergoing less than total or near-total thyroidectomy as an initial surgical treatment, will need reoperation for incidentally found thyroid carcinoma on final histopathology to provide complete resection of possible multicentric disease or to allow for efficient radioiodine therapy. In the 2015 American Thyroid Association guidelines for the management of thyroid cancer, completion thyroidectomy was offered to patients for whom a bilateral thyroidectomy would have been recommended had the diagnosis been available before the initial surgery. Older age (>45 years), contralateral suspicious thyroid nodules, a personal history of radiation therapy to the head and neck, and the existence of familial differentiated thyroid cancer should be taken into account to recommend a bilateral procedure to facilitate either radioiodine therapy or follow-up. Since a significant proportion of thyroid surgery is still being performed by low-volume surgeons, the discovery of large remnant tissue even after so-called total thyroidectomy is not a rare issue. To enhance the safety and success of completion thyroidectomies, new technologies and guiding methods are being used more often including intraoperative nerve monitoring, preoperative and intraoperative USG mapping, and gamma surgical probe.


Thyroid cancer Completion thyroidectomy Radioguided surgery 


  1. 1.
    Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411–7.CrossRefGoogle Scholar
  2. 2.
    Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013;23:449–55. Scholar
  3. 3.
    Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941–6.CrossRefGoogle Scholar
  4. 4.
    Langer JE, Agarwal R, Zhuang H, Huang SS, Mandel SJ. Correlation of findings from iodine 123 scan and ultrasonography in the recommendation for thyroid fine-needle aspiration biopsy. Endocr Pract. 2011;17:699–706. Scholar
  5. 5.
    Yoo WS, Choi HS, Cho SW, Moon JH, Kim KW, Park HJ, et al. The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance. Clin Endocrinol. 2014;80:735–42. Scholar
  6. 6.
    Gweon HM, Son EJ, Youk JH, Kim JA. Thyroid nodules with Bethesda system III cytology: can ultrasonography guide the next step? Ann Surg Oncol. 2013;20:3083–8. Scholar
  7. 7.
    Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, et al. Development of a clinical decision model for thyroid nodules. BMC Surg. 2009;9:12. Scholar
  8. 8.
    Goldstein RE, Netterville JL, Burkey B, Johnson JE. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg. 2002;235:656–62.CrossRefGoogle Scholar
  9. 9.
    Mehta RS, Carty SE, Ohori NP, Hodak SP, Coyne C, LeBeau SO, et al. Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery. 2013;154:730–6. Scholar
  10. 10.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. Scholar
  11. 11.
    Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68–79. Scholar
  12. 12.
    Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9. Scholar
  13. 13.
    Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Ann Surg Oncol. 2014;21:1379–83. Scholar
  14. 14.
    Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. Ann Surg Oncol. 2012;19:4217–22. Scholar
  15. 15.
    Soylu L, Aydin OU, Ozbas S, Bilezikci B, Ilgan S, Gursoy A, et al. The impact of the multifocality and histologic subtype of papillary thyroid carcinoma on central compartment lymph node metastasis. Eur Rev Med Pharmacol Sci. 2016;20:3972–9.PubMedGoogle Scholar
  16. 16.
    Aydin OU, Soylu L, Ozbas S, Ilgan S, Bilezikci B, Gursoy A, et al. The risk of hypoparathyroidism after central compartment lymph node dissection in the surgical treatment of pT1, N0 thyroid papillary carcinoma. Eur Rev Med Pharmacol Sci. 2016;20:1781–7.PubMedGoogle Scholar
  17. 17.
    Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels GH. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up. Thyroid. 2012;22:369–76. Scholar
  18. 18.
    Santra A, Bal S, Mahargan S, Bal C. Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer. Nucl Med Commun. 2011;32:52–8. Scholar
  19. 19.
    Erbil Y, Barbaros U, Deveci U, Kaya H, Bozbora A, Ozbey N, et al. Gamma probe-guided surgery for revision thyroidectomy: in comparison with conventional technique. J Endocrinol Investig. 2005;28:583–8.CrossRefGoogle Scholar
  20. 20.
    Ilgan S, Ozbas S, Bilezikci B, Sengezer T, Aydin OU, Gursoy A, et al. Radioguided occult lesion localization for minimally invasive parathyroidectomy: technical consideration and feasibility. Nucl Med Commun. 2014;35:1167–74. Scholar
  21. 21.
    Ilgan S, Oztürk E, Yildiz R, Emer O, Ayan A, Görgülü S, et al. Combination of preoperative ultrasonographic mapping and radioguided occult lesion localization in patients with locally recurrent/persistent papillary thyroid carcinoma: a practical method for central compartment reoperations. Clin Nucl Med. 2010;35:847–52. Scholar
  22. 22.
    Robert JA, Mazzaferri EL. I-131 therapy in a patient with a large thyroid remnant. In: Robert JA, Mazzaferri EL, editors. Essentials of thyroid cancer management. New York: Springer; 2005. p. 257–60.Google Scholar
  23. 23.
    Lang BH, Wong CKH, Wong KP, Chu KK, Shek TWH. Effect of thyroid remnant volume on the risk of hypothyroidism after hemithyroidectomy: a prospective study. Ann Surg Oncol. 2017;24:1525–32. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Serdar Özbaş
    • 1
  • Seyfettin Ilgan
    • 2
  1. 1.Department of SurgeryGüven HospitalAnkaraTurkey
  2. 2.Department of Nuclear MedicineGüven HospitalAnkaraTurkey

Personalised recommendations